Smoke without fire? Researchers question heated tobacco products

Industry Insight
Jul.22.2022

Heated tobacco products have soared in popularity as a "smoke free" alternative to cigarettes in recent years, but a peer-reviewed report has suggested their emissions could be considered smoke—a claim strongly rejected by the tobacco industry.

 

Smoke without fire? Researchers question heated tobacco products

Heated tobacco products, or HTPs, are often confused with e-cigarettes, which heat liquid that can contain nicotine but do not involve tobacco leaf.

HTPs instead use a high heat to decompose tobacco, via a process called pyrolysis, which does not set it on fire or burn it, therefore avoiding creating smoke.

 

The most popular and widely available HTP, Philip Morris International's IQOS, is an electronic device that heats a tobacco-filled, paper-wrapped, cigarette-like stick at a temperature of up to 350 degrees Celsius (662 degrees Fahrenheit).

 

Last month a review of the available research by experts in pyrolysis from Britain's Nottingham University found "chemical evidence that IQOS emissions fit the definition of both an aerosol and smoke."

 

The paper, published in the American Chemical Society's Omega journal, was funded by the STOP anti-tobacco initiative.

Its lead author Clement Uguna said that IQOS emissions contain chemical compounds that are "in normal tobacco smoke, bush burning and wood smoke".

 

"Hence smoke arises simply by heating organic substances and does not necessarily involve fire," he told AFP.

 

The paper also found that previous research on IQOS—the majority of which has been funded by the tobacco industry—had compared a stick to a typical cigarette.

 

However IQOS sticks are much smaller, containing around 200 milligrams of tobacco compared to 645 milligrams for a standard cigarette, it said.

 

Because research by Philip Morris International (PMI) did not use a "like against like" comparison, it "underestimated" the levels of harmful and potentially harmful constituents (HPHCs) from IQOS, the review added.

 

PMI said the level of HPHCs in IQOS emissions—per stick—was "reduced on average by 90-95 percent compared to cigarette smoke".

 

However that level fell to 68 percent when comparing the tobacco content of the two products, the Nottingham University experts said, calling for more research.

 

'Not smoke': PMI

 

PMI told AFP that the paper "misleadingly leverages pieces of the scientific assessment while omitting other important pieces of evidence".

 

"Numerous international combustion experts and a number of government agencies have reviewed the same evidence package and concluded that the IQOS aerosol produced is not smoke," it said.

 

Reto Auer, a doctor at Germany's University of Bern who has previously researched heated tobacco, praised the Omega paper, telling AFP it was "one of the rare reports to dare to tackle the question of 'smoke' so deeply".

 

Jamie Hartmann-Boyce of the Centre for Evidence-Based Medicine at Oxford University, an author of a highly regarded review on HTP science published earlier this year, said the "important" paper "made some very good points".

 

"I think mechanistically there are a lot of reasons to suspect HTPs might be more harmful than e-cigarettes and possibly less harmful than traditional cigarettes—but we really need more data," she told AFP.

 

'Difficult balance'

 

IQOS is available in more than 60 countries under widely varying regulations, and sticks come in flavours such as menthol, cherry and grape, which critics say help attract younger users.

 

Last month the European Commission proposed banning flavoured HTP varieties after stick sales in the EU soared more than 2,000 percent—from 934 million to nearly 20 billion—between 2018 and 2020.

 

PMI told AFP that the "proposal from the Commission is not underpinned by evidence".

 

"It fails to prove, for instance, that flavours pose any additional health risks or that they attract a significant proportion of non-nicotine users," it said.

 

Hartmann-Boyce said "there is every reason to be concerned about the extent to which the tobacco industry is manipulating the science and messages around new tobacco products."

 

But she warned it was a "difficult balance" to communicate the risks of such products because of the overwhelming damage done by cigarettes. Tobacco kills half its users, according to the World Health Organization.

 

"If we say something is safer than cigarettes, that is not saying it's safe—it's like saying that this knife is safer than a loaded gun," Hartmann-Boyce said.

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
PMI Expands U.S. ZYN Portfolio With New 1.5 mg and 8 mg Strengths, Moves Toward a Unified 20-Pouch-Per-Can Format
Philip Morris International is expanding its U.S. ZYN nicotine pouch portfolio with new 1.5 mg and 8 mg strengths and plans to move its core 3 mg and 6 mg dry-pouch products from 15 to 20 pouches per can in the fourth quarter of 2026. ZYN ULTRA is also commercially available, with FDA authorization covering 10 products at 9 mg and one 11 mg Smooth product. PMI U.S. lists the new 1.5 mg and 8 mg strengths as commercially available, but as of September 10 they do not appear on the FDA’s public authorization list. Public materials do not identify which PMTA submissions cover the two new strengths or their current review status.
Sep.11
Major U.S.  Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
Major U.S. Vape Distributor Demand Vape Pays at Least $300,000 for White House Lobbying Amid Enforcement Pressure
New York vape distributor Ecto World, which operates as Demand Vape, hired political consultant Roger Stone to lobby the Executive Office of the President on regulation of vaping and related products while facing state enforcement and multiple lawsuits. Public lobbying disclosures show that Ecto World paid at least $300,000 for the work through June 30, 2026. Separately, New York State announced in March that more than 28,500 pounds of vaping products tied to the company had been seized, while New York City and the state have pursued legal or enforcement actions. Public records do not show that the lobbying directly changed any specific regulatory or enforcement outcome.
Sep.08
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
From Product Innovation to Integrated Solutions: NEXTECH Expands Its Global Heated Tobacco Solutions
NEXTECH launched its NEXE Pro circumferential-heating tobacco stick globally at InterTabac 2026, as the company expands from product innovation into broader heated tobacco solutions. Amid intensifying competition across global HTP markets, NEXTECH is strengthening its R&D, manufacturing and pre-launch support capabilities to serve different types of business customers.
Industry Insight
Sep.15
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
Earnings Analysis | CTIHK H1 2026 Revenue Falls 26.9% as Core Businesses Diverge and New Growth Drivers Remain to Be Proven
China Tobacco International (HK) reported a 26.9% revenue decline in H1 2026, while gross profit fell only 9.5%, revealing sharp divergence across its businesses. Tobacco leaf imports contracted, while leaf exports and Brazil operations expanded strongly. Cigarette exports faced China duty-free market transition, and new tobacco products remained small. Meanwhile, CTIHK continues to strengthen its role as an investment and financing platform, though major external deals have yet to emerge. 2Firsts examines what these shifts mean for its next growth drivers.
Capital Markets
Aug.24
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia Extends Illicit Tobacco Crackdown From Tougher Penalties to Customs and Logistics Supply Chains
Australia's federal government introduced a new illicit tobacco enforcement bill on September 10 that would strengthen evidentiary presumptions, representative sampling, seizure and forfeiture procedures, proceeds-of-crime powers and obligations for customs and logistics operators. The proposal follows the Combatting Illicit Tobacco Act 2026, which took effect in August and increased penalties while expanding investigative and asset-recovery tools. Together, the reforms extend Australia's crackdown from tougher criminal sanctions into import, logistics and evidentiary enforcement.
Sep.14